Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

Herb Greenberg, 'Herb on the Street' author, joins 'Power Lunch' to discuss Greenberg's thoughts on the terminated ...

Hims & Hers fell by 34.63 percent on Monday to close at $41.98 apiece after Novo Nordisk terminated its marketing partnership ...

Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial ...

U.S. stocks went up and oil prices fell this week as investors hoped that Iran would not block the global supply of oil, even ...

The Novo Nordisk partnership ending does not alter my long-term bullish thesis on HIMS; the company is much more than just a ...

Hims & Hers Health, a telehealth company, offers direct-to-patient platform to distribute prescription drugs and OTC ...

It’s not often that investors come across the kind of companies that can yield a multi-bagger investment over the years.

Novo Nordisk ends Wegovy deal with Hims over legal issues, sending the stock tumbling. What happens next? Here's a look.

Stock markets have rallied after U.S. President Donald Trump announced a ceasefire in the Israel-Iran conflict, although the ...

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...